Health Care : Current Reviews

Methylene blue as rescue therapy for COVID-19 patients who failed to respond to other therapies

Joint Webinar: 14^th International Conference on Clinical Case Reports & 6^th International Conference on Pediatrics and Healthcare & 10^th World Summit on Oncology and Cancer Science

November 24, 2022 | Webinar

Daryoush Hamidi Alamdari

Mashhad University of Medical Sciences, Iran

Posters & Accepted Abstracts: Health Care Curr Rev

Abstract:

There is currently no consensus on specific pharmacological treatments for COVID-19 and there is debate about the efficacy and safety of antiviral drugs. This study verified the effect of the reduced form of Methylene blue (MB) as the last option of treatment to rescue patients who did not respond to Remdesivir, Interferon-β, and Favipiravir therapies. Oral MB (1 mg/kg every eight hours for two days, followed by 1mg/ kg every 12 hours for the next days) was administered to 83 severe patients who did not respond to antiviral drugs and were in critical condition. 72 patients recovered completely, and 11 patients did not survive. For the treatment of COVID-19 patients, in addition to fluid therapy and oxygen support, different types of drugs are required simultaneously, such as anti-viral agents, antibiotics, anticoagulants, immunomodulatory drugs, and antioxidants. MB possesses all of these properties along with anti-hypoxemia and antirespiratory distress features and can therefore be included in the clinical management of COVID-19. Clinical trial: NCT04370288, IRCT20191228045924N120.